|
Abilify Patient Information, Aripiprazole Patient Information- HealthyPlace.com (799 words) |
 | Abilify is used in the treatment of schizophrenia, the crippling psychological disorder that causes its victims to lose touch with reality, often triggering hallucinations, delusions, and disorganized thought. |
| Abilify is also approved for the treatment of acute manic and mixed episodes associated with Bipolar Disorder. |
| Abilify can cause tardive dyskinesia, a condition marked by involuntary movements in the face and body, including chewing movements, puckering, puffing the cheeks, and sticking out the tongue. |
| What is Abilify? (513 words) |
| Abilify (generic name aripiprazole) was approved for the treatment of schizophrenia on November 15, 2002 by the U.S. Food and Drug Administration. |
| By contrast, Abilify actually has the ability, under certain circumstances, to stimulate the D2 receptor and is technically called a "partial D2 agonist." Animal studies suggest that when levels of dopamine in the brain are low, Abilify may enhance the dopamine effect by stimulating the D2 receptor. |
| Abilify was studied in 1,238 patients with an acute relapse of schizophrenia before the FDA approved it. |
Feeds |
Contact